Research programme: HuMax-TAC antibodies - Genmab

Drug Profile

Research programme: HuMax-TAC antibodies - Genmab

Alternative Names: HuMax-TAC

Latest Information Update: 18 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ADC Therapeutics; Genmab
  • Developer Genmab
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 2 inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Transplant rejection

Most Recent Events

  • 18 Mar 2011 No development reported - Preclinical for Transplant rejection in Denmark (Parenteral)
  • 06 Aug 2007 The HuMax-TAC antibodies are still in preclinical trials for the prevention of organ transplant rejection in Denmark
  • 06 Aug 2007 Merck Serono terminates its worldwide licence for the lead HuMax-TAC antibody candidate
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top